Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma

被引：2
作者：
Itoh, Shinji [1 ]
Ikeda, Masafumi [2 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan
[2] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Japan
来源：
HEPATOBILIARY SURGERY AND NUTRITION | 2022年
关键词：
D O I：
10.21037/hbsn-22-432
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
    Castet, Florian
    Willoughby, Catherine E.
    Haber, Philipp K.
    Llovet, Josep M.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1827 - 1829
  • [22] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
    Hoang, H. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
  • [23] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Esmail, Abdullah
    Xu, Jiaqiong
    Burns, Ethan A.
    Abboud, Karen
    Sheikh, Ali
    Umoru, Godsfavour
    Gee, Kelly
    Wiechmann, Catherine
    Zhang, Yuqi
    Abdelrahim, Maen
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [24] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Reika Yamauchi
    Takanori Ito
    Sachiyo Yoshio
    Takafumi Yamamoto
    Kazuyuki Mizuno
    Masatoshi Ishigami
    Hiroki Kawashima
    Satoshi Yasuda
    Shigeo Shimose
    Hideki Iwamoto
    Taiji Yamazoe
    Taizo Mori
    Eiji Kakazu
    Takumi Kawaguchi
    Hidenori Toyoda
    Tatsuya Kanto
    Journal of Gastroenterology, 2023, 58 : 565 - 574
  • [25] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Yoo, Changhoon
    Hong, Jung Yong
    Kim, Han Sang
    Lee, Dae-Won
    Lee, Myung Ah
    Kim, Jin Won
    Kim, Ilhwan
    Oh, Sang-Bo
    Hwang, Jun-Eul
    Chon, Hong Jae
    Lim, Ho Yeong
    LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
  • [26] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Yamauchi, Reika
    Ito, Takanori
    Yoshio, Sachiyo
    Yamamoto, Takafumi
    Mizuno, Kazuyuki
    Ishigami, Masatoshi
    Kawashima, Hiroki
    Yasuda, Satoshi
    Shimose, Shigeo
    Iwamoto, Hideki
    Yamazoe, Taiji
    Mori, Taizo
    Kakazu, Eiji
    Kawaguchi, Takumi
    Toyoda, Hidenori
    Kanto, Tatsuya
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (06) : 565 - 574
  • [27] Treatment of hepatocellular carcinoma in Child-Pugh B patients
    Piscaglia, Fabio
    Terzi, Eleonora
    Cucchetti, Alessandro
    Trimarchi, Chiara
    Granito, Alessandro
    Leoni, Simona
    Marinelli, Sara
    Pini, Patrizia
    Bolondi, Luigi
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (10) : 852 - 858
  • [28] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
    Cappuyns, Sarah
    Pique-Gili, Marta
    Esteban-Fabro, Roger
    Philips, Gino
    Pinyol, Roser
    Vandecaveye, Vincent
    Abril-Fornaguera, Jordi
    Haber, Philipp
    Verslype, Chris
    Van Cutsem, Eric
    Lambrechts, Diether
    Villanueva, Augusto
    Dekervel, Jeroen
    Llovet, Josep M.
    HEPATOLOGY, 2023, 78 : S1871 - S1872
  • [29] A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
    Watanabe, Yukinobu
    Ogawa, Masahiro
    Tamura, Yu
    Suda, Seiichiro
    Kaneko, Masahiro
    Kumagawa, Mariko
    Hirayama, Midori
    Matsumoto, Naoki
    Yamamoto, Toshiki
    Moriyama, Mitsuhiko
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2021, 9
  • [30] Atezolizumab/Bevacizumab in hepatocellular carcinoma
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2020, 26 (10): : 970 - 971
12345